ArticleAntimicrobial agents and chemotherapy2012
Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.Antimicrobial resistance and infection control · 2019Pooled it
- Pooled it
- Characterizing Ertapenem Neurotoxicity: A Systematic Review and Experience at a Tertiary Medical Center.Open forum infectious diseases · 2024Trial
- Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.BMC infectious diseases · 2017Trial
- Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.The Journal of antimicrobial chemotherapy · 2016Trial
- Antibiotic-Resistant Bacteria in Drinking Water Across Twelve Regions of Ghana: Strengthening Evidence for National Surveillance.Tropical medicine and infectious disease · 2025Article
- Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-ProducingAntimicrobial agents and chemotherapy · 2022Article
- Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Article
- Overcoming Multidrug Resistance of Antibiotics via Nanodelivery Systems.Pharmaceutics · 2022Review
- Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-ProducingAntimicrobial agents and chemotherapy · 2021Article
- Emergence of Resistance inAntimicrobial agents and chemotherapy · 2021Article
- An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused byInfection and drug resistance · 2021Article
- Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Clinical microbiology reviews · 2018Review
- Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.Journal of clinical microbiology · 2018Review
- Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2017Review
- Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?Journal of clinical microbiology · 2014Article
- Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.World journal of gastroenterology · 2014Review
- Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.Therapeutic advances in infectious disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.